The European Commission has approved the use of Kyprolis (carfilzomib) in combination with Revlimid® and dexamethasone as a treatment for relapsed myeloma patients who have received at least one previous line of treatment. This follows the recent recommendation by the European Medicines Agency (EMA) based on the pivotal ASPIRE trial which showed that Kyprolis in combination with Revlimid and dexamethasone significantly enhanced progression-free survival compared to Revlimid and dexamethasone alone (26.3 vs 17.6 months respectively). Kyprolis is currently being appraised by the National Institute for Health and Care Excellence (NICE) for routine use in the UK. Final guidance is expected in Spetember 2016.


Read full article